Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- ED Awareness Campaign Successful: Pfizer
October 28, 2002
- JMA Strongly Opposed Operation of Hospitals by Profit-making Corporations
October 28, 2002
- Korosho Study Group Recommends AUTs for OTC Drugs
October 21, 2002
- OTC NEWS IN BRIEF
October 21, 2002
- ON THE MOVE
October 21, 2002
- Tanabe Stresses Enhancement of Competitiveness as Research-oriented Firm: President Hayama
October 21, 2002
- Fujisawa Introduces Atlas Data Suit from Gene Logic
October 21, 2002
- WORLD NEWS IN BRIEF
October 21, 2002
- Gov't-managed Health Insurance Posts Record-high Deficit
October 21, 2002
- Hisamitsu Licenses Keto Patch to Sigma-Tau in Italy
October 21, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
October 21, 2002
- Asahi Kasei to Spin Off 7 Divisions in October 2003
October 21, 2002
- The 3rd Kitasato Harvard Symposium Focuses on Global Drug Development
October 21, 2002
- BUSINESS NEWS IN BRIEF -1-
October 21, 2002
- Drug Organization Gives Grants to 5 Basic Research Projects
October 21, 2002
- BUSINESS NEWS IN BRIEF -2-
October 21, 2002
- Hac-Kimisawa: Semi-annual Consolidated Sales Up 4.4%
October 21, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
October 21, 2002
- Kirindo: Sales, Profits Up in 1st Half
October 21, 2002
- Drugs Not Requiring Manufacturing or Import Approval Revised
October 21, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…